Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation
Nature Communications Open Access 06 May 2022
-
Investigating the influence of physiologically relevant hydrostatic pressure on CHO cell batch culture
Scientific Reports Open Access 08 January 2021
-
Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab
BMC Molecular and Cell Biology Open Access 21 January 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Walsh, G. Biopharmaceutical benchmarks. Nat. Biotechnol. 24, 769–776 (2006).
Rader, R. Paucity of biopharma approvals raises alarm. GEN 28, 3–15 (2008).
Evers, P. The Future of the Biological Market (Business Insights, March 2010).
R&D Pipeline News. Special edition, March 2010. La Merie Business Intelligence, available at http://www.pipelinereview.com
Scheinecker, C. et al. Tocilizumab. Nat. Rev. Drug Discov. 8, 273–274 (2009).
Melmed, G. et al. Certolizumab pegol. Nat. Rev. Drug Discov. 7, 641–642 (2008).
Keam, S. Harper, D.M. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed). BioDrugs 22, 205–208 (2008).
Crum, C., Jones, C., Kirkpatrick, P. Quadrivalent human papillomavirus recombinant vaccine. Nat. Rev. Drug Discov. 5, 629–630 (2006).
Schneider, C.K. & Kalinke, U. Towards biosimilar monoclonal antibodies. Nat. Biotechnol. 26, 985–990 (2008).
Carlson, B. Biosimilar market fails to meet projections. GEN 29, 43–45 (2009).
Mackler, B.F. Biosimilars and follow on branded biologics. GEN 29, 89–92 (2009).
The top 10 biosimilars players; positioning performance and SWOT analysis (Business Insights, April 2009) Available at http://www.globalbusinessinsights.com
Westphal, N.J. & Malecki, M.J. Biosimilars 2007–2017: Shifting Payer and Physician Opinion Increases the Hurdles to Uptake (Decision Resources, October, 2008).
Drunker, D.J. et al. Liraglutide. Nat. Rev. Drug Discov. 9, 267–268 (2010).
Walsh, G. & Jefferis, R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24, 1241–1252 (2006).
Ceaglio, N. et al. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Biochimie 90, 437–449 (2008).
Trousdale, R.K. et al. Efficacy of native and hyperglycosylated follicle-stimulating hormone analogs for promoting fertility in female mice. Fertil. Steril. 91, 265–270 (2009).
Zhu, Y. et al. Carbohydrate-remodelled acid α-glucosidase with higher affinity for the cation-independent mannose 6 phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem. J. 389, 619–628 (2005).
Zhu, Y. et al. Glycoengineered acid α-glucosidase with improved efficacy at correcting the metabolic aberrations & motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17, 954–963 (2009).
Natsume, A. Niwa, R., Satoh, M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des. Devel. Ther. 3, 7–16 (2009).
Hamilton, S.R. et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313, 1441–1443 (2006).
DePalma, A. Single use systems make headway with sceptics. GEN 29, 27–31 (2009).
Browne, S.M. & Al-Rubeai, M. Selection methods for high producing mammalian cell lines. Trends Biotechnol. 25, 425–432 (2007).
Durocher, Y. & Butler, M. Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol. 20, 700–707 (2009).
Liu, C. & Downey, W. Contract manufacturing demands remain strong. GEN 29, 53–59 (2009).
DePalma, A. Removing impediments in downstream processing. GEN 29, 135–139 (2009).
Davis, M.E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1071 (2010).
Hiller, A. Fast growth foreseen for protein therapeutics. GEN 29, 153–155 (2009).
Goodman, M. Sales of biologics to show robust growth through to 2013. Nat. Rev. Drug Discov. 8, 837 (2009).
Sheridan, C. Fresh from the biologic pipeline—2009. Nat. Biotechnol. 28, 307–310 (2010).
Chinese Market for Biopharmaceuticals, Asia Market Information and Development Company, March 2009. Available via http://www.reportlinker.com
Chakraborty, C. & Agoramoorthy, G. A special report on India's biotech scenario: advancement in biopharmaceutical and healthcare sectors. Biotechnol. Adv. 28, 1–6 (2010).
Netterwald, J. Stem cell technologies regenerative medicine. 29, 39–42 (2009).
Vierbuchen, T. et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035–1041 (2010).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Walsh, G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 28, 917–924 (2010). https://doi.org/10.1038/nbt0910-917
Issue Date:
DOI: https://doi.org/10.1038/nbt0910-917
This article is cited by
-
Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation
Nature Communications (2022)
-
Valine feeding reduces ammonia production through rearrangement of metabolic fluxes in central carbon metabolism of CHO cells
Applied Microbiology and Biotechnology (2022)
-
Separation of closely related monoclonal antibody charge variant impurities using poly(ethylenimine)-grafted cation-exchange chromatography resin
3 Biotech (2022)
-
Investigating the influence of physiologically relevant hydrostatic pressure on CHO cell batch culture
Scientific Reports (2021)
-
Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab
BMC Molecular and Cell Biology (2020)